by microbiome | Sep 6, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work
Immunotherapy has revolutionized the treatment of several cancers. However, it remains elusive why only some patients benefit from these treatments and why some patients experience immune-related adverse events (irAEs). Microbiomes are under investigation to...
by microbiome | Jun 23, 2023 | Highlights, News
Vaiomer is participating in «la 10e édition des AFSSI Connexions» on July 04 and 05 in Montpellier Vaiomer’s representatives, Anne DEFLISQUE (Sales & Marketing Director), Benjamin Lelouvier (Chief Scientific Officer), and Céline RIBIERE (Microbiome Scientist),...
by microbiome | Jun 23, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work
Immunotherapies (Immune Checkpoint Inhibitors, ICI) have become a powerful therapeutic strategy for treating a variety of cancers. It is a very exciting area but with challenges. Indeed, the patient response to these therapies is often heterogeneous and not durable,...
by microbiome | Jun 22, 2023 | Highlights, News
Vaiomer is happy to announce its participation to “la deuxième édition de la journée microbiote de MetaGenopolis” on June 27 in Paris, FRANCE Vaiomer is looking forward to exchanging and sharing novelties with scientists, academics, hospitals, and...
by microbiome | Jun 12, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work
Numerous metagenomics-based studies have associated gut microbiota dysbiosis with the progression and resistance to immunotherapy of intestinal and non-intestinal cancers. It remains unclear whether the dysbiosis is causing the tumorigenic process or the consequence...
